Ginkgo Bioworks to Acquire Zymergen

Ginkgo Bioworks Acquires Assets from Bitome

June 6, 2022

Biotechnology

Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.

Ginkgo Bioworks Acquires Novogy's Microbial Engineering Platform

December 16, 2020

Biotechnology

Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.

Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

May 11, 2021

AI & Machine Learning

Ginkgo Bioworks agreed to a business combination with special purpose acquisition company Soaring Eagle Acquisition Corp., which would result in Ginkgo becoming a publicly listed company. The transaction is expected to close in the third quarter of 2021 and is expected to provide up to $2.5 billion of gross cash proceeds, including $775 million from a PIPE.

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Ginkgo Bioworks Acquires Proof Diagnostics

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.

Zymergen Acquires enEvolv

March 19, 2020

Biotechnology

Zymergen has acquired enEvolv, a synthetic biology company that provides ultra-high throughput microbial screening and engineering. The acquisition brings enEvolv's biosensor-driven platform and team into Zymergen to accelerate discovery and commercialization of biologically-manufactured materials across electronics, consumer care, agriculture and other end markets.